Adlai Nortye Ltd. (ANL) Form 6-K — Aug 3, 2026

Adlai Nortye Ltd. announced that it has submitted a Clinical Trial Notification to the Australian Therapeutic Goods Administration and received approval from the Human Research Ethics Committee to commence a Phase I clinical trial for AN4035. AN4035 is a first-in-class antibody drug conjugate targeting CEACAM5 and armed with a pan-RAS(ON) inhibitor payload, designed to treat RAS-addicted solid tumors while minimizing systemic toxicity. The global Phase I trial will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of AN4035 as both a monotherapy and in combination with cetuximab.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.